spacer
home > ict > spring 2018 > exponential developments
PUBLICATIONS
International Clinical Trials

Exponential Developments

“The expected exposure in humans at a dose to be given, in comparison to the exposure at which certain effects were observed in animals or earlier in the study in humans, is considered more relevant than the relative dose levels between animals and humans,” claims the first-in-human (FIH) guidance.

In July 2017, the EMA revised its guidance on FIH clinical trials, providing strategies to identify and mitigate risks for trial participants. This article explores how modern clinical study strategies can be utilised in early phase studies to not only satisfy the new regulatory risk mitigation guidance principles, but also incorporate efficiencies in study design and certainty of decision-making. The purpose of this article is not to restate information that has been provided in earlier FIH guidance documents, but to highlight the new recommendations being suggested.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bradley Joblin has a doctorate from the University of Zurich, Switzerland. Having held senior management and director positions in clinical research at the headquarters of global pharmaceutical companies and smaller biotechnology companies, his experience is in clinical study implementation, early and late phase clinical study design, and clinical development strategy. Brad founded his own company providing clinical study and development advice to the clinical research community including biotech companies and medical research institutes. He joined Q-Pharm at the start of 2017 to offer scientific oversight and management within Q-Pharm, as well as study design and development strategies to clients.
spacer
Bradley Joblin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement